Amedisys (AMED) Scheduled to Post Earnings on Wednesday

Amedisys (NASDAQ:AMED) is set to post its quarterly earnings results after the market closes on Wednesday, April 28th. Analysts expect Amedisys to post earnings of $1.43 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, February 23rd. The health services provider reported $1.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.02. Amedisys had a return on equity of 26.41% and a net margin of 8.22%. The company had revenue of $550.71 million for the quarter, compared to analyst estimates of $551.91 million. During the same period in the prior year, the company posted $0.94 EPS. On average, analysts expect Amedisys to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Shares of AMED opened at $281.04 on Wednesday. The business’s 50 day moving average is $267.09 and its two-hundred day moving average is $271.06. Amedisys has a 52-week low of $165.42 and a 52-week high of $325.12. The firm has a market cap of $9.23 billion, a price-to-earnings ratio of 56.32, a PEG ratio of 3.18 and a beta of 0.77. The company has a quick ratio of 0.94, a current ratio of 0.94 and a debt-to-equity ratio of 0.40.

In related news, CFO Scott G. Ginn sold 975 shares of the company’s stock in a transaction on Friday, January 29th. The stock was sold at an average price of $286.87, for a total transaction of $279,698.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Denise M. Bohnert sold 454 shares of the company’s stock in a transaction on Monday, January 25th. The stock was sold at an average price of $314.41, for a total value of $142,742.14. Following the transaction, the insider now owns 7,925 shares of the company’s stock, valued at $2,491,699.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,382 shares of company stock valued at $1,209,687. 2.80% of the stock is owned by company insiders.

A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft upped their target price on Amedisys from $275.00 to $340.00 and gave the company a “buy” rating in a research report on Monday, February 8th. They noted that the move was a valuation call. Benchmark upped their target price on Amedisys from $275.00 to $325.00 and gave the company a “buy” rating in a research report on Monday, March 1st. Finally, Truist boosted their price target on Amedisys from $280.00 to $325.00 in a report on Tuesday, January 5th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Amedisys has a consensus rating of “Buy” and a consensus target price of $268.64.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More: What Are Treasury Bonds?

Earnings History for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.